News
Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback